Teva Reinforces Focus On Advancing Multiple Sclerosis Treatment At 31st ECTRIMS Congress

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that data on COPAXONE® (glatiramer acetate injection), the most prescribed therapy for relapsing forms of multiple sclerosis (MS) globally, and laquinimod, an investigational therapy being evaluated in relapsing and progressive forms of MS, will be featured at the 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Barcelona, October 7-10, 2015.

Help employers find you! Check out all the jobs and post your resume.